Ozempic injection pen next to a Daminoc EAA Complex package on a light marble surface

Ozempic – everything you need to know

Ozempic and GLP-1 medications: effects, muscle loss and what you can do about it

More and more people are using GLP-1 medications such as Ozempic to lose weight. These are prescription medicines: Ozempic (the active ingredient semaglutide) has been approved in the EU for type 2 diabetes since 2018, and the same ingredient was approved for overweight and obesity as Wegovy in 2022. [6] [7] The effect is impressive: in the large STEP 1 trial, adults with overweight or obesity without diabetes lost around 15 percent of their body weight on semaglutide over 68 weeks, compared with 2.4 percent on placebo. [1] But part of the weight lost is lean mass – and that includes muscle. What that means and how to counter it is what this article covers.

What is Ozempic and how does it work?

Semaglutide mimics the body’s own gut hormone GLP-1 and activates its receptors – among others in the appetite centers of the brain, in the gut and in the pancreas. As a result, appetite falls, gastric emptying slows, and insulin release is stimulated in a blood-sugar-dependent way while the release of its counterpart glucagon is dampened. [1] The weight loss comes mainly from the lower calorie intake – not from a “boosted metabolism”.

There is evidence for the heart too: in the SELECT trial, semaglutide reduced the risk of major cardiovascular events by 20 percent in people with overweight or obesity and existing cardiovascular disease, but without diabetes. [5]

What studies show about muscle loss

Losing weight with GLP-1 medications does not only burn fat. In the body-composition subgroup of STEP 1 (measured by DXA), lean mass also fell on semaglutide – by 9.7 percent from baseline. [2] A review across several studies estimates that about 25 to 39 percent of the weight lost on such medications can be lean mass. [3] For context: lean mass is not just muscle – it also includes water and organ tissue. And because fat shrank faster, the share of lean mass in total body weight even rose slightly in STEP 1. [2]

Risks and side effects

The most common side effects are gastrointestinal complaints such as nausea, vomiting, diarrhea or constipation; they can occur mainly at the start and during dose increases and are usually mild to moderate and temporary. [6] [1] Gallbladder problems, including gallstones, are also documented – rapid weight loss can promote them. [1] The product information also names acute pancreatitis as a risk – one more reason this therapy belongs under medical supervision. [7]

And the yo-yo effect is real: in the STEP 1 extension, about two thirds of the lost weight came back within a year of stopping. [4] Obesity is a chronic condition with many contributing factors – so the long-term strategy belongs under medical guidance.

The role of ultra-processed foods

One reason many people struggle to lose weight is the high share of ultra-processed products in everyday life. In a controlled trial, participants on an ultra-processed diet ate on average around 500 kilocalories more per day and gained weight – on an unprocessed diet with the same portion sizes on offer, they did not. [8] Above all, the trial shows that what we eat influences how much we eat – a lever that matters regardless of any medication.

Protecting muscle: training and protein

Both measures are well supported by the literature: four professional societies advise combining GLP-1 therapy with a structured exercise program and an adequate, individually adjusted protein intake [13]; in a randomized weight-maintenance trial, the combination of liraglutide and exercise reduced body fat more than either measure alone [14]. In detail:

  • Strength training: Regular resistance training provides the stimulus the body needs to keep muscle.
  • Enough protein: A higher protein intake is proven to help preserve lean mass in a calorie deficit – especially combined with strength training. [10] In training studies, supplemental protein increased gains in muscle mass and strength – up to an intake of about 1.6 grams per kilogram of body weight per day; that is a value from these studies, not a dosing rule for GLP-1 therapy. [11]
  • Essential amino acids: They are the building blocks that directly trigger muscle protein synthesis – the ISSN confirms this role in its position stand. [9]

Topping up amino acids: where Daminoc fits

When appetite runs low on GLP-1 therapy, every meal counts. This is where Daminoc comes in: it provides the nine essential amino acids plus arginine, modeled on the human amino acid profile. [12] It is a practical way to support your baseline supply of exactly the building blocks the body needs for muscle protein synthesis and the ongoing renewal of tissue. [9] That is particularly useful if you eat little, or your body uses protein less efficiently with age.

This way, Daminoc complements your diet with exactly the amino acids your body needs for muscle and tissue renewal [9, 12] – practical on any day, whatever your appetite.

Conclusion: effective, but not on autopilot

GLP-1 medications such as Ozempic can make losing weight considerably easier – but they are a tool, not a shortcut. What helps preserve muscle – strength training and adequate protein – is also explicitly recommended by professional societies for GLP-1 therapy [13]; in a randomized weight-maintenance trial, the combination of liraglutide and exercise improved body composition more than either measure alone [14]. Side effects belong in clinical assessment. And because much of the lost weight can return after stopping, it is worth planning the long-term strategy with your doctor from the outset – as are starting and dosing.

Sources

  1. Trial: Semaglutide 2.4 mg in overweight and obesity (STEP 1, New England Journal of Medicine, 2021)
  2. Analysis: Body composition on semaglutide in STEP 1 (Journal of the Endocrine Society, 2021)
  3. Review: Medication-induced weight loss and skeletal muscle (The Lancet Diabetes & Endocrinology, 2024)
  4. Study: Weight regain after semaglutide withdrawal (STEP 1 extension, Diabetes Obesity and Metabolism, 2022)
  5. Trial: Semaglutide and cardiovascular events in overweight or obesity with existing cardiovascular disease, without diabetes (SELECT, New England Journal of Medicine, 2023)
  6. Approval documents: Ozempic (European Medicines Agency)
  7. Approval documents: Wegovy (European Medicines Agency)
  8. Trial: Ultra-processed diets raise calorie intake and weight (Cell Metabolism, 2019)
  9. Position stand: Essential amino acids and skeletal muscle (ISSN, 2023)
  10. Position stand: Diets and body composition (ISSN, 2017)
  11. Meta-analysis: Protein supplementation and resistance training (British Journal of Sports Medicine, 2018)
  12. Daminoc: product and ingredients
  13. Joint advisory: Nutritional priorities to support GLP-1 therapy for obesity (ACLM, ASN, OMA and TOS, Obesity, 2025)
  14. Trial: Healthy weight loss maintenance with exercise, liraglutide, or both combined (New England Journal of Medicine, 2021)